EZDERM vs Dermoscopy Two Step Algorithm

EZDERM is a free, stand-alone companion app that can only be used with a web-based service. EZDERM is a truly mobile, cloud-based Electronic Health Record (EHR) designed specifically for dermatologists and their staff. Designed by practicing dermatologists – and not engineers – EZDERM enables users to break free from the constraints of desktop computers and practice the way they want to, not the way they have to. EZDERM is based on patent-pending 3D Body Maps, an amazingly intuitive visual interface that empowers dermatologists and their staff to visually document patient encounters. With over 3,000 anatomical locations, users find themselves at the nexus of precision and simplicity. Users can quickly schedule patients, record allergies and medications, and generate biopsy requisition forms— all on the iPad. In addition, users have the ability to take and draw on photographs, use robust voice recognition, and utilize a vast array of features designed to make the user’s office more efficient and productive. Simply smarter and built in 3D, EZDERM truly is one dimension above the competition. FEATURES: Patent-Pending 3D Body Map with over 3,000 Anatomical Locations Cloud-Based Dermatology Specific Features Meaningful Use Certified SureScripts Certified Nuance Speech Recognition and Speech Commands Scheduling Real-time Coding Built for ICD-10 100% Secure

This app is intended to help you interpret the dermoscopic patterns seen with your dermatoscope. You will be asked a series of questions that will lead you to the most probable diagnosis. This app also contains over 80 photos and charts to help you in your diagnosis. No internet connection needed to view the full app. It is all ready for super quick image and information retrieval. There are also 50 interactive cases to solve. Each case starts with a clinical and dermoscopic image and ends with a labelled dermoscopic image pointing out critical structures. This app is based on the 2 step algorithm with the first step involving the determination of whether the lesion is a melanocytic. Melanocytic lesions will be divided into nevi or lesions with varying levels of suspicion for melanoma based on melanoma specific patterns and common nevi patterns. Non-melanocytic lesions will be analyzed to determine if they are suspicious for basal cell carcinoma or squamous cell carcinoma. Common benign lesions such as dermatofibroma, seborrheic keratoses and hemangiomas will be positively identified to avoid unnecessary biopsies. This app will increase your ability to detect skin cancers with greater accuracy thereby decreasing unnecessary biopsies and missing less early melanomas and nonmelanoma skin cancers. Check out https://usatinemedia.com to learn more and watch a video demo of this app narrated by Dr. Richard P. Usatine. Authors: Ashfaq A. Marghoob, MD Memorial Sloan-Kettering Cancer Center New York, New York Richard P. Usatine, MD University of Texas Health Science Center San Antonio, Texas Natalia Jaimes, MD Aurora Skin Cancer Center and Universidad Pontificia Bolivariana Medellin, Colombia To learn more dermoscopy from these authors, see www.americandermoscopy.com. Disclaimer: This app is intended for the education of healthcare professionals and not as a diagnostic and treatment reference for the general population. Disclaimer: While this app may help you in rendering a correct diagnosis, it is not intended to entirely replace the findings on patient history and physical examination including examination of the lesion with side lighting and touch. The final diagnosis rests on properly assimilating the information gained from the patient history, thorough naked eye physical examination, and meticulous dermoscopic inspection of the lesion. 3Gen, Inc. is the sponsor of this app. Visit www.dermlite.com to see their complete line of skin imaging devices. Developed by Usatine Media Richard P. Usatine, MD, Co-President, Professor of Family & Community Medicine, Professor of Dermatology and Cutaneous Surgery, University of Texas Health San Antonio Peter Erickson, Co-President, Lead Software Developer